An interventional study of Brain Imaging in Stroke, Ischemic, Inflammatory Response and Stroke, Acute, sponsored by Imperial College London. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2021-06-30.
Sponsored by Imperial College London · Not applicable, Interventional, and Basic science
DESIGN: exploratory, prospective, natural history, imaging cohort study
BACKGROUND: Stroke causes a strong inflammatory response in the brain which is thought to contribute to permanent brain damage in stroke patients. To develop new therapies targeting inflammation we need to better understand how inflammation affects the injured brain tissue and how it relates to neurological deficits that directly affect the patients' quality of life.
AIMS: To track the extent and location of inflammation in the brain after stroke over a period of 90 days. The study will explore whether the most inflamed areas in the brain undergo the most damage after stroke and correspond to the cognitive and neurological deficits experienced by stroke patients.
METHODS: The study involves an initial screening visit and 2 study imaging visits at days 15 and 90 after the stroke episode. Patients will undergo:
Venous cannula will be inserted into the forearm for the duration of the scans.
POPULATION: 15- 25 patients (recruitment will cease once 15 patients have completed the study)
ELIGIBILITY: Male and female stroke patients, aged 18-85, with a recent (within last 10 days) ischemic stroke of moderate severity, able and willing to provide informed consent
LOCATION: Patients will be recruited at the Charing Cross Hospital, Imperial College Healthcare NHS Trust, and study scans will be performed by Invicro Centre for Imaging Sciences, Hammersmith Hospital
DURATION: 18 months FUNDED BY: Biogen Idec Ltd
Stroke is a leading cause of mortality and serious long-term disability. There is a substantial unmet medical need for new therapies that can improve outcomes in acute stroke.
Experimental and pathologic data suggest that peri-infarct inflammation contributes to secondary injury after brain ischemia and that blocking inflammation could reduce the volume of brain infarction and improve clinical outcome.
In a recently completed phase 2 placebo-controlled clinical trial, the administration of natalizumab (a potent inhibitor of leukocyte transmigration through the blood -brain barrier [BBB]) in the hyperacute phase of ischemic stroke was associated with beneficial effects in measures of functional outcome, but did not affect the rate of infarct volume growth during a 90-day assessment period. This apparent discrepancy between the lack of effect of anti-inflammatory therapy on lesion size and a substantial beneficial effect on functional outcome in ischemic stroke patients has raised further questions about the manifestation of neuroinflammation, its pathophysiological role and its relation to patients' functional outcome in stroke patients.
The purpose of this imaging study is to characterize the subacute and longstanding extent of upregulation of the neuroinflammation marker TSPO on glial cells at two time points after stroke. The study will also explore the correlation of TSPO upregulation with measures of stroke severity and post-stroke functional outcomes.
The objectives of this study are:
The endpoints that relate to these objectives are:
This is an exploratory, prospective, natural history, imaging cohort study. The recruiting site will be Imperial College Healthcare NHS Trust. All study scans will be performed by Invicro, Hammersmith Hospital
Between 15 and 25 subjects, with recruitment ending when 15 participants have completed all study procedures.
Subjects aged 18-85 with a supratentorial ischemic stroke of moderate severity as measured by NIHSS >4 and evidence of infarction on clinical brain scan at time of stroke:
Subjects will participate in this study for approximately 90 days. No treatment will be started as part of the trial
7,283 studies on the registry are indexed under Stroke; 2,013 are open to participants now.
This study's enrollment of 3 is below the median of 50 across 5,366 interventional studies indexed under Stroke.
Browse Stroke studies →Imperial College London is the lead sponsor of 824 studies on the registry; 178 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Acute stroke cohort
Diagnostic Test: Brain Imaging
The study involves an initial screening visit and 2 study imaging visits at days 15 and 90 after the stroke episode.Patients will undergo: 1. Two 90-minute brain imaging sessions using Positron Emission Tomography (PET) (involves injection of safe radiotracers which attach to brain immune cell markers TSPOs and light up the inflamed areas in the brain), 2. Two 45-90 minute Magnetic Resonance Imaging (MRI) scanning sessions (include administration of safe chemical contrast agent Gadolinium), 3. Physical and neurological examinations (vital signs, assessments of mobility and cognitive functioning), 4. Blood testing (routine measurements, blood inflammation markers, and genetic testing for TSPO marker). Venous cannula will be inserted into the forearm for the duration of the scans.
Also known as: Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET-CT)
Changes in TSPO Radiotracer Uptake Infarct Area
PET-derived measures of TSPO radiotracer uptake in the infarct and peri-infarct areas at day 90 after a stroke (compared with Day 15)
Time frame: 90 days
Changes in TSPO Radiotracer Uptake Distant Area
PET-derived measures of TSPO radiotracer uptake in ROIs distant from the infarct area (e.g. thalamus, hippocampi, amygdalae and midbrain) at day 90 after a stroke (compared with Day 15)
Time frame: 90 days
| Milestone | Acute Stroke Cohort |
|---|---|
| Started | 3 |
| Completed | 2 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
PET-derived measures of TSPO radiotracer uptake in the infarct and peri-infarct areas at day 90 after a stroke (compared with Day 15)
| g/mL | Acute Stroke Cohort |
|---|---|
| Changes in TSPO Radiotracer Uptake Infarct Area | 1.54 ± 0.39 |
PET-derived measures of TSPO radiotracer uptake in ROIs distant from the infarct area (e.g. thalamus, hippocampi, amygdalae and midbrain) at day 90 after a stroke (compared with Day 15)
| g/mL | Acute Stroke Cohort |
|---|---|
| Changes in TSPO Radiotracer Uptake Distant Area | 0.89 ± 0.04 |
Collected over 90 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Acute Stroke Cohort | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
Participants with clinical and radiological acute supratentorial ischaemic stroke within the previous 10 days
| Age, Categorical(Participants) | Acute Stroke Cohort |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 2 |
| >=65 years | 1 |
| Sex: Female, Male(Participants) | Acute Stroke Cohort |
|---|---|
| Female | 2 |
| Male | 1 |
| Ethnicity (NIH/OMB)(Participants) | Acute Stroke Cohort |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 3 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Acute Stroke Cohort |
|---|---|
| United Kingdom | 3 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: Undecided
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Infectious Encephalitis
Imperial College London